1232 related articles for article (PubMed ID: 23069990)
1. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?
Bell JL; Wächter K; Mühleck B; Pazaitis N; Köhn M; Lederer M; Hüttelmaier S
Cell Mol Life Sci; 2013 Aug; 70(15):2657-75. PubMed ID: 23069990
[TBL] [Abstract][Full Text] [Related]
2. Subcellular localization and RNP formation of IGF2BPs (IGF2 mRNA-binding proteins) is modulated by distinct RNA-binding domains.
Wächter K; Köhn M; Stöhr N; Hüttelmaier S
Biol Chem; 2013 Aug; 394(8):1077-90. PubMed ID: 23640942
[TBL] [Abstract][Full Text] [Related]
3. The biological function of IGF2BPs and their role in tumorigenesis.
Du QY; Zhu ZM; Pei DS
Invest New Drugs; 2021 Dec; 39(6):1682-1693. PubMed ID: 34251559
[TBL] [Abstract][Full Text] [Related]
4. The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer.
Lederer M; Bley N; Schleifer C; Hüttelmaier S
Semin Cancer Biol; 2014 Dec; 29():3-12. PubMed ID: 25068994
[TBL] [Abstract][Full Text] [Related]
5. Abrogating the interplay between IGF2BP1, 2 and 3 and IGF1R by let-7i arrests hepatocellular carcinoma growth.
Fawzy IO; Hamza MT; Hosny KA; Esmat G; Abdelaziz AI
Growth Factors; 2016 Feb; 34(1-2):42-50. PubMed ID: 27126374
[TBL] [Abstract][Full Text] [Related]
6. IGF2BP1 enhances an aggressive tumor cell phenotype by impairing miRNA-directed downregulation of oncogenic factors.
Müller S; Bley N; Glaß M; Busch B; Rousseau V; Misiak D; Fuchs T; Lederer M; Hüttelmaier S
Nucleic Acids Res; 2018 Jul; 46(12):6285-6303. PubMed ID: 29660014
[TBL] [Abstract][Full Text] [Related]
7. EGR2-mediated regulation of m
Ying Y; Ma X; Fang J; Chen S; Wang W; Li J; Xie H; Wu J; Xie B; Liu B; Wang X; Zheng X; Xie L
Cell Death Dis; 2021 Jul; 12(8):750. PubMed ID: 34326314
[TBL] [Abstract][Full Text] [Related]
8. Recognition of RNA N
Huang H; Weng H; Sun W; Qin X; Shi H; Wu H; Zhao BS; Mesquita A; Liu C; Yuan CL; Hu YC; Hüttelmaier S; Skibbe JR; Su R; Deng X; Dong L; Sun M; Li C; Nachtergaele S; Wang Y; Hu C; Ferchen K; Greis KD; Jiang X; Wei M; Qu L; Guan JL; He C; Yang J; Chen J
Nat Cell Biol; 2018 Mar; 20(3):285-295. PubMed ID: 29476152
[TBL] [Abstract][Full Text] [Related]
9. A novel lncRNA MTAR1 promotes cancer development through IGF2BPs mediated post-transcriptional regulation of c-MYC.
Gao Y; Jiang M; Guo F; Liu X; Zhang Q; Yang S; Yeung YT; Yang R; Wang K; Wu Q; Zhang D; Zhang C; Laster KV; Ge M; Nie W; Liu K; Dong Z
Oncogene; 2022 Oct; 41(42):4736-4753. PubMed ID: 36109629
[TBL] [Abstract][Full Text] [Related]
10. IMPs: an RNA-binding protein family that provides a link between stem cell maintenance in normal development and cancer.
Degrauwe N; Suvà ML; Janiszewska M; Riggi N; Stamenkovic I
Genes Dev; 2016 Nov; 30(22):2459-2474. PubMed ID: 27940961
[TBL] [Abstract][Full Text] [Related]
11. miR-1275: A single microRNA that targets the three IGF2-mRNA-binding proteins hindering tumor growth in hepatocellular carcinoma.
Fawzy IO; Hamza MT; Hosny KA; Esmat G; El Tayebi HM; Abdelaziz AI
FEBS Lett; 2015 Aug; 589(17):2257-65. PubMed ID: 26160756
[TBL] [Abstract][Full Text] [Related]
12. The role of Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) as m
Sun CY; Cao D; Du BB; Chen CW; Liu D
Int J Biol Sci; 2022; 18(7):2744-2758. PubMed ID: 35541906
[TBL] [Abstract][Full Text] [Related]
13. A pan-cancer landscape of IGF2BPs and their association with prognosis, stemness and tumor immune microenvironment.
Shao W; Zhao H; Zhang S; Ding Q; Guo Y; Hou K; Kan Y; Deng F; Xu Q
Front Oncol; 2022; 12():1049183. PubMed ID: 36686749
[TBL] [Abstract][Full Text] [Related]
14. IGF2BP family of RNA-binding proteins regulate innate and adaptive immune responses in cancer cells and tumor microenvironment.
Elcheva IA; Gowda CP; Bogush D; Gornostaeva S; Fakhardo A; Sheth N; Kokolus KM; Sharma A; Dovat S; Uzun Y; Schell TD; Spiegelman VS
Front Immunol; 2023; 14():1224516. PubMed ID: 37503349
[TBL] [Abstract][Full Text] [Related]
15. Targeting insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) for the treatment of cancer.
Cai Y; Wang Y; Mao B; You Q; Guo X
Eur J Med Chem; 2024 Mar; 268():116241. PubMed ID: 38382391
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA FGF13-AS1 inhibits glycolysis and stemness properties of breast cancer cells through FGF13-AS1/IGF2BPs/Myc feedback loop.
Ma F; Liu X; Zhou S; Li W; Liu C; Chadwick M; Qian C
Cancer Lett; 2019 May; 450():63-75. PubMed ID: 30771425
[TBL] [Abstract][Full Text] [Related]
17. Control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic RNPs.
Weidensdorfer D; Stöhr N; Baude A; Lederer M; Köhn M; Schierhorn A; Buchmeier S; Wahle E; Hüttelmaier S
RNA; 2009 Jan; 15(1):104-15. PubMed ID: 19029303
[TBL] [Abstract][Full Text] [Related]
18. Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential.
Zhu TY; Hong LL; Ling ZQ
Biomark Res; 2023 Jun; 11(1):62. PubMed ID: 37280679
[TBL] [Abstract][Full Text] [Related]
19. Co-transcriptional R-loops-mediated epigenetic regulation drives growth retardation and docetaxel chemosensitivity enhancement in advanced prostate cancer.
Ying Y; Wu Y; Zhang F; Tang Y; Yi J; Ma X; Li J; Chen D; Wang X; Liu X; Liu B; Luo J; Zheng X; Xie L
Mol Cancer; 2024 Apr; 23(1):79. PubMed ID: 38658974
[TBL] [Abstract][Full Text] [Related]
20. Regulatory mechanisms and therapeutic implications of insulin-like growth factor 2 mRNA-binding proteins, the emerging crucial m
Zhou H; Sun Q; Feng M; Gao Z; Jia S; Cao L; Yu X; Gao S; Wu H; Li K
Theranostics; 2023; 13(12):4247-4265. PubMed ID: 37554271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
